The role of Alpha1-Adrenergic Receptors Promoter Methylation in Cerebral Autoregulation in Fetus
α1-肾上腺素能受体启动子甲基化在胎儿大脑自动调节中的作用
基本信息
- 批准号:10657080
- 负责人:
- 金额:$ 38.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-07 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAdrenergic AgentsAdrenergic AgonistsAdrenergic ReceptorAnimalsBasic ScienceBiological AssayBirthBlood PressureBlood flowBrainBrain InjuriesCarotid ArteriesCatecholaminesCatheterizationCerebrovascular CirculationCerebrumChronicDNADNA MethylationDataDisabled PersonsEpigenetic ProcessExcisionFaceFamilyFemaleFetal SheepFetusGene ExpressionGestational AgeHistone AcetylationHomeostasisHormonesHumanHypermethylationImpairmentIncidenceInfantKnowledgeLaser-Doppler FlowmetryLearning DisabilitiesLifeLow Birth Weight InfantLuciferasesMeasurementMeasuresMethylationNervous SystemNeurologicNewborn InfantOrganismOutcomePathway interactionsPhenylephrinePlayPremature BirthPremature InfantRegulationReporterResearchRoleRuptureSeriesSheepSideStressStructure of superior cervical ganglionSystemSystemic blood pressureTestingTherapeuticTimealpha-1 adrenergic receptorsblood pressure elevationcerebral capillarycognitive disabilityconstrictiondifferential expressiondisabilityexperimental studyfetalhistone modificationin uteroin vivoinsightlife-long learningmaleneonatepressurepreterm newbornpreventpromoterreceptorresponsesextransmission process
项目摘要
Summary: The ability of an organism to reduce the brain blood flow in response to sudden surges in systemic blood pressure
(BP) is known as cerebral autoregulation (CAR). In contrast to term neonates, preterm neonates are not able to reduce
cerebral blood flow (CBF) in response to increased systemic BP. In preterm neonates, this exposes fragile cerebral vessels
to a significantly increased blood flow at high pressure, leading to their rupture and brain damage. Our preliminary studies
demonstrate that near-term fetuses can constrict carotid arteries and reduce CBF when systemic BP rises; however, this
capability is not developed in the preterm fetus. We also observed that the constriction of carotid arteries to reduce CBF is
regulated by the adrenergic nervous system, specifically by the activities of alpha-1 adrenergic receptors (α1-ARs). These
receptors are expressed at a significantly lower number in preterm carotid arteries. Also, we observed that following the
removal of adrenergic control in the near-term fetus by severing the superior cervical ganglion (SCG) made them lose their
ability to reduce carotid blood flow (CaBF) to the brain with the rise in systemic BP. Thus, after the removal of SCG, both
preterm and near-term fetuses cannot reduce CBF following an increase in systemic BP. During ex-vivo experiments on
carotid segments, we observed that preterm arterial constriction in response to α1-ARs agonist was significantly lower than
those from near-term lambs. Thus, we concluded that reduced activities of α1-ARs play a fundamental role in regulating
CaBF with the rise in systemic BP. We also observed that the reduction in the activities of α1-ARs agonists in preterm
resulted from reduced expression of α1-ARs compared to those in near-term fetal lambs. Furthermore, we present evidence
that DNA hypermethylation reduces α1-ARs promoter activities by luciferase reporter assays and the involvement of histone
modifications. Thus, we will test the hypothesis that promoter DNA hypermethylation and histone modifications reduce the
expression and function of α1-AR subtypes (α1A-, α1B-, α1D) in the carotid arteries and play an essential role in the maturation
of cerebral autoregulation from preterm to term fetus. We will also collect data from both sexes (male versus female) to
identify sex-related changes. The studies will be conducted ex-vivo on isolated carotid arteries and in vivo in chronically
catheterized fetal sheep. The hypothesis will be tested with two specific aims. Aim 1: From preterm to term fetus in a sex-
specific manner, we will conduct an in-depth mechanistic analysis of promoter DNA methylation and histone modifications
on differential expression of α1-AR subtypes in carotid arteries. Aim 2: From preterm to term fetus, in a sex-specific manner,
we will determine the functional significance of differential α1-AR subtypes promoter methylation, histone modifications,
and gene expression on carotid artery contractility and blood flow regulation to the brain in response to an increase in
systemic pressure. The measurements will be conducted in real-time, in-vivo, with in-utero fetal maturation every week
from 105 to 137 days. This will provide valuable information regarding the role of α1-AR subtypes and the epigenetic
mechanisms involved in the maturation of CAR.
摘要:生物体响应全身血压突然升高而减少脑血流量的能力
(BP)被称为大脑自动调节(CAR)。与足月新生儿相比,早产儿无法减少
脑血流量(CBF)响应全身血压升高。对于早产儿,这会暴露脆弱的脑血管
高压下血流量显着增加,导致破裂和脑损伤。我们的初步研究
证明当全身血压升高时,近期胎儿可以收缩颈动脉并减少 CBF;然而,这
早产儿的能力尚未发育。我们还观察到,通过收缩颈动脉来减少 CBF
受肾上腺素能神经系统,特别是 α1 肾上腺素能受体 (α1-AR) 的活性调节。这些
早产儿颈动脉中受体的表达量明显较低。此外,我们观察到,以下
通过切断颈上神经节(SCG)来消除近期胎儿的肾上腺素能控制,使他们失去了
随着全身血压升高,减少流向大脑的颈动脉血流 (CaBF) 的能力。因此,去除 SCG 后,两者
早产儿和近足月胎儿在全身血压升高后不能降低 CBF。在离体实验中
在颈动脉段中,我们观察到 α1-AR 激动剂引起的早产动脉收缩明显低于
来自近期羔羊的那些。因此,我们得出结论,α1-ARs 活性的降低在调节中发挥着基础作用。
CaBF 随全身血压升高而变化。我们还观察到,早产儿中 α1-AR 激动剂的活性降低
与近足月胎儿羔羊相比,α1-AR 表达减少所致。此外,我们还提供证据
通过荧光素酶报告基因检测和组蛋白的参与,DNA 高甲基化降低了 α1-AR 启动子活性
修改。因此,我们将检验以下假设:启动子 DNA 高甲基化和组蛋白修饰会降低
α1-AR 亚型(α1A-、α1B-、α1D)在颈动脉中的表达和功能,并在成熟过程中发挥重要作用
从早产儿到足月胎儿的大脑自动调节。我们还将收集两性(男性与女性)的数据,以
识别与性别相关的变化。这些研究将在离体的颈动脉上进行,并在体内长期进行。
对胎羊进行导管插入。该假设将通过两个具体目标进行检验。目标 1:从早产儿到足月胎儿
具体方式,我们将对启动子DNA甲基化和组蛋白修饰进行深入的机制分析
颈动脉中α1-AR亚型的差异表达。目标 2:从早产儿到足月胎儿,以特定性别的方式,
我们将确定差异 α1-AR 亚型启动子甲基化、组蛋白修饰的功能意义,
以及基因表达对颈动脉收缩力和大脑血流调节的影响
系统压力。测量将在体内实时进行,每周胎儿在宫内成熟
从 105 天到 137 天。这将提供有关 α1-AR 亚型和表观遗传作用的有价值的信息。
CAR 成熟的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ravi Goyal其他文献
Ravi Goyal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ravi Goyal', 18)}}的其他基金
Alpha Adrenergic Methylation and Developmental Maturation of Cerebral Autoregulation in Ovine Preterm Fetus
羊早产儿的α肾上腺素能甲基化和大脑自动调节的发育成熟
- 批准号:
10661985 - 财政年份:2023
- 资助金额:
$ 38.38万 - 项目类别:
Modeling and simulation tools for optimizing design of network-informed clinical trials of combination HIV prevention interventions
用于优化 HIV 预防联合干预措施的网络信息临床试验设计的建模和模拟工具
- 批准号:
10622168 - 财政年份:2022
- 资助金额:
$ 38.38万 - 项目类别:
Epigenetic Mechanisms of Developmental Regulation of Fetal, Newborn, and Adult Cerebral Artery Sympathetic Innervation and Alpha1 Adrenergic Receptor Subtypes
胎儿、新生儿和成人脑动脉交感神经支配和α1肾上腺素能受体亚型发育调节的表观遗传机制
- 批准号:
9237948 - 财政年份:2016
- 资助金额:
$ 38.38万 - 项目类别:
Mechanisms of acclimatization responses of fetal and adult cerebral artery alpha1 adrenergic receptor subtypes to long-term hypoxia
胎儿和成人脑动脉α1肾上腺素能受体亚型对长期缺氧的适应反应机制
- 批准号:
9072344 - 财政年份:2016
- 资助金额:
$ 38.38万 - 项目类别:
Cerebral Artery Alpha1 Adrenergic and PKC Regulatory Mechanisms
脑动脉 Alpha1 肾上腺素能和 PKC 调节机制
- 批准号:
8811457 - 财政年份:2015
- 资助金额:
$ 38.38万 - 项目类别:
RAF KINASE AND EPIGENETIC REGULATION OF FETAL VASCULAR DEVELOPMENT
RAF 激酶和胎儿血管发育的表观遗传调控
- 批准号:
9134923 - 财政年份:2015
- 资助金额:
$ 38.38万 - 项目类别:
Role of LincRNA in Developmental Regulation of Angiogenesis
LincRNA 在血管生成发育调控中的作用
- 批准号:
8768569 - 财政年份:2014
- 资助金额:
$ 38.38万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 38.38万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 38.38万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 38.38万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 38.38万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 38.38万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 38.38万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 38.38万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 38.38万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 38.38万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 38.38万 - 项目类别:














{{item.name}}会员




